277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis

2018 ◽  
Vol 154 (6) ◽  
pp. S-68 ◽  
Author(s):  
Dana J. Lukin ◽  
Aaron Weiss ◽  
Satimai Aniwan ◽  
Siri Kadire ◽  
Gloria Tran ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tumor Necrosis Factor ◽  
Propensity Score ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Antagonist ◽  
Antagonist Therapy ◽  
Inflammatory Bowel ◽  
Comparative Safety ◽  
Factor Antagonist ◽  
Necrosis Factor

scholarly journals Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease

2017 ◽  
Vol 49 (10) ◽  
pp. 1086-1091 ◽  
Author(s):  
James O. Lindsay ◽  
Alessandro Armuzzi ◽  
Javier P. Gisbert ◽  
Bernd Bokemeyer ◽  
Laurent Peyrin-Biroulet ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tumor Necrosis Factor ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Antagonist ◽  
Antagonist Therapy ◽  
Inflammatory Bowel ◽  
Factor Antagonist ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document